Abstract：
OBJECTIVE: To explore the association between gabapentin use and the risk of dementia in patients with chronic pain, considering the rising concerns of dementia in an aging population and the potential cognitive impacts of chronic pain management.
METHODS: A nested case-control study utilizing data from a longitudinal health insurance database.
METHODS: The study is based on a longitudinal health insurance database spanning 2000-2019 in Taiwan.
METHODS: A total of 201,492 patients aged 50 years and older diagnosed with chronic pain between 2001 and 2017 were included. The study focused on individuals with chronic pain, excluding those diagnosed with dementia a year before or after their chronic pain diagnosis.
METHODS: Analysis of gabapentin prescription history was conducted, considering the cumulative dose from the chronic pain diagnosis date to the dementia diagnosis date or equivalent period for controls.
METHODS: Data included demographics, gabapentin prescription history, and comorbidities. Logistic regression was used to estimate odds ratios for dementia risk.
RESULTS: No significant difference in the risk of dementia was found between low and high cumulative doses of gabapentin. The adjusted odds ratio for dementia risk associated with gabapentin use was 0.91 (95 % C.I. 0.83-1.01), indicating no substantial increase in risk.
CONCLUSIONS: Long-term Gabapentin therapy for chronic pain is not associated with a differential risk of dementia across dosage levels, irrespective of age or gender. Further study into its potential cognitive impacts is essential.
METHODS: A nested case-control study utilizing data from a longitudinal health insurance database.
METHODS: The study is based on a longitudinal health insurance database spanning 2000-2019 in Taiwan.
METHODS: A total of 201,492 patients aged 50 years and older diagnosed with chronic pain between 2001 and 2017 were included. The study focused on individuals with chronic pain, excluding those diagnosed with dementia a year before or after their chronic pain diagnosis.
METHODS: Analysis of gabapentin prescription history was conducted, considering the cumulative dose from the chronic pain diagnosis date to the dementia diagnosis date or equivalent period for controls.
METHODS: Data included demographics, gabapentin prescription history, and comorbidities. Logistic regression was used to estimate odds ratios for dementia risk.
RESULTS: No significant difference in the risk of dementia was found between low and high cumulative doses of gabapentin. The adjusted odds ratio for dementia risk associated with gabapentin use was 0.91 (95 % C.I. 0.83-1.01), indicating no substantial increase in risk.
CONCLUSIONS: Long-term Gabapentin therapy for chronic pain is not associated with a differential risk of dementia across dosage levels, irrespective of age or gender. Further study into its potential cognitive impacts is essential.
摘要：
目的：探讨慢性疼痛患者使用加巴喷丁与痴呆风险的关系。考虑到老龄化人群对痴呆症的担忧日益增加，以及慢性疼痛管理的潜在认知影响。
方法：利用纵向健康保险数据库中的数据进行嵌套病例对照研究。
方法：该研究基于台湾2000-2019年的纵向健康保险数据库。
方法：纳入了2001年至2017年间诊断为慢性疼痛的年龄在50岁及以上的201,492例患者。这项研究的重点是慢性疼痛患者，不包括那些在慢性疼痛诊断之前或之后一年被诊断患有痴呆症的人。
方法：分析加巴喷丁处方史，考虑从慢性疼痛诊断日期到痴呆诊断日期或对照组的等效时间的累积剂量。
方法：数据包括人口统计学，加巴喷丁处方史,和合并症。使用Logistic回归估计痴呆风险的比值比。
结果：在低和高累积剂量加巴喷丁之间，痴呆风险没有发现显著差异。与加巴喷丁使用相关的痴呆风险的调整比值比为0.91（95％C.I.0.83-1.01），表明风险没有实质性增加。
结论：长期加巴喷丁治疗慢性疼痛与不同剂量水平的痴呆风险无关。不论年龄或性别。进一步研究其潜在的认知影响至关重要。
方法：利用纵向健康保险数据库中的数据进行嵌套病例对照研究。
方法：该研究基于台湾2000-2019年的纵向健康保险数据库。
方法：纳入了2001年至2017年间诊断为慢性疼痛的年龄在50岁及以上的201,492例患者。这项研究的重点是慢性疼痛患者，不包括那些在慢性疼痛诊断之前或之后一年被诊断患有痴呆症的人。
方法：分析加巴喷丁处方史，考虑从慢性疼痛诊断日期到痴呆诊断日期或对照组的等效时间的累积剂量。
方法：数据包括人口统计学，加巴喷丁处方史,和合并症。使用Logistic回归估计痴呆风险的比值比。
结果：在低和高累积剂量加巴喷丁之间，痴呆风险没有发现显著差异。与加巴喷丁使用相关的痴呆风险的调整比值比为0.91（95％C.I.0.83-1.01），表明风险没有实质性增加。
结论：长期加巴喷丁治疗慢性疼痛与不同剂量水平的痴呆风险无关。不论年龄或性别。进一步研究其潜在的认知影响至关重要。
